Cancer name Head and Neck Squamous Cell Carcinoma
Cancer Type HNSC
Immunotherapy type Oncolytic viruses
Treatment Newcastle disease virus(NDV)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature MX2
Official Symbol MX2
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trail
Description Infection with NDV resulted in strong upregulation of a number of immune-related genes, including type I IFN–related transcripts and transcripts encoding a range of chemokines
PMID 29504948
Title PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy